Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P. Sundahl N, et al. Among authors: fonteyne v. J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3. J Transl Med. 2017. PMID: 28662677 Free PMC article. Clinical Trial.
Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study.
Heumann P, Aguado-Barrera ME, Avuzzi B, Azria D, Briers E, Bultijnck R, Choudhury A, De Ruysscher D, Farcy-Jacquet MP, Fonteyne V, Gómez Caamaño A, Helmbold I, Johnson K, Kerns SL, Lambrecht M, Lingard Z, Rancati T, Rosenstein BS, Sperk E, Paul Symonds R, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Webb A, West CM, Chang-Claude J, Seibold P; REQUITE Consortium. Heumann P, et al. Among authors: fonteyne v. Radiother Oncol. 2023 Jan;178:109426. doi: 10.1016/j.radonc.2022.11.015. Epub 2022 Nov 25. Radiother Oncol. 2023. PMID: 36442608 Free article.
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types.
Naderi E, Aguado-Barrera ME, Schack LMH, Dorling L, Rattay T, Fachal L, Summersgill H, Martínez-Calvo L, Welsh C, Dudding T, Odding Y, Varela-Pazos A, Jena R, Thomson DJ, Steenbakkers RJHM, Dennis J, Lobato-Busto R, Alsner J, Ness A, Nutting C, Gómez-Caamaño A, Eriksen JG, Thomas SJ, Bates AM, Webb AJ, Choudhury A, Rosenstein BS, Taboada-Valladares B, Herskind C, Azria D, Dearnaley DP, de Ruysscher D, Sperk E, Hall E, Stobart H, Chang-Claude J, De Ruyck K, Veldeman L, Altabas M, De Santis MC, Farcy-Jacquet MP, Veldwijk MR, Sydes MR, Parliament M, Usmani N, Burnet NG, Seibold P, Symonds RP, Elliott RM, Bultijnck R, Gutiérrez-Enríquez S, Mollà M, Gulliford SL, Green S, Rancati T, Reyes V, Carballo A, Peleteiro P, Sosa-Fajardo P, Parker C, Fonteyne V, Johnson K, Lambrecht M, Vanneste B, Valdagni R, Giraldo A, Ramos M, Diergaarde B, Liu G, Leal SM, Chua MLK, Pring M, Overgaard J, Cascallar-Caneda LM, Duprez F, Talbot CJ, Barnett GC, Dunning AM, Vega A, Andreassen CN, Langendijk JA, West CML, Alizadeh BZ, Kerns SL; Radiogenomics Consortium. Naderi E, et al. Among authors: fonteyne v. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad088. doi: 10.1093/jncics/pkad088. JNCI Cancer Spectr. 2023. PMID: 37862240 Free PMC article.
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer.
Joseph N, Cicchetti A, McWilliam A, Webb A, Seibold P, Fiorino C, Cozzarini C, Veldeman L, Bultijnck R, Fonteyne V, Talbot CJ, Symonds PR, Johnson K, Rattay T, Lambrecht M, Haustermans K, De Meerleer G, Elliott RM, Sperk E, Herskind C, Veldwijk M, Avuzzi B, Giandini T, Valdagni R, Azria D, Jacquet MF, Charissoux M, Vega A, Aguado-Barrera ME, Gómez-Caamaño A, Franco P, Garibaldi E, Girelli G, Iotti C, Vavassori V, Chang-Claude J, West CML, Rancati T, Choudhury A. Joseph N, et al. Among authors: fonteyne v. Front Oncol. 2022 Oct 26;12:937934. doi: 10.3389/fonc.2022.937934. eCollection 2022. Front Oncol. 2022. PMID: 36387203 Free PMC article.
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W. De Meerleer G, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20421155
Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
Ost P, Speleers B, De Meerleer G, De Neve W, Fonteyne V, Villeirs G, De Gersem W. Ost P, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):920-6. doi: 10.1016/j.ijrobp.2010.04.025. Epub 2010 Aug 2. Int J Radiat Oncol Biol Phys. 2011. PMID: 20675077
152 results